Navigation Links
EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
Date:6/11/2008

Patent Covers Compositions and Methods

ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance of U.S. Patent No. 7,371,741 covering analogs of 2- methoxyestradiol (2ME2). The patent grants EntreMed composition-of-matter and method of use intellectual property protection through 2025 for analogs of 2ME2 in oncology and a broad range of non-oncology indications, including inflammatory and immune disorders, rheumatoid arthritis, and other diseases characterized by abnormal cell division (mitosis).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Analogs of 2ME2 have been developed by EntreMed to improve metabolic stability and retain or enhance antiproliferative and antiangiogenic properties. Preclinical results demonstrate that certain analogs of 2ME2 can attack tumors on multiple fronts -- directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells, through inhibition of mitosis and induction of apoptosis, and by blocking blood vessels that feed tumors (angiogenesis inhibition).

U.S. Patent No. 7,371,741 entitled "Estradiol derivatives and pharmaceutical compositions using same," covers analogs that have been modified at certain positions on the 2-methoxyestradiol structure, yet retain their ability to inhibit cell proliferation. In addition, the '741 patent claims methods for treating tumors with compounds having the claimed structural modifications of 2-methoxyestradiol. The '741 patent covering the issued claims is owned exclusively by EntreMed.

James S. Burns, EntreMed President & Chief Executive Officer, commented, "This patent is the result of an extensive internal program to identify novel compounds based on our expertise in angiogenesis, cell cycle regulation and cell signaling. This patent further strengthens our intellectual property position in next generation antimitotic and antiangiogenic drugs for the treatment of cancer. ENMD-1198, a lead compound resulting from our analog program, is currently in a Phase 1 study in advanced cancers. We anticipate completion of the study in the second half of 2008. Additional studies, including an expanded Phase 1 or Phase 2 trial, are planned for later this year."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/10/2017)...  Shane K. Burchfield, DPM, is recognized by Continental Who,s Who ... in Alabama . Dr. Burchfield ... He brings over 20 years of experience, as well as expertise ... his role. "The ... to welcome you to his practice," the company,s website ...
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... June 22, 2017 , ... Groove Ring is excited to announce they've ... performance silicon wedding bands and all-purpose rings. Whether you’re an athlete, adventurer, professional, or ... just for you. , From the rock face to the auto shop, Groove Ring ...
(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/20/2017)... ... 20, 2017 , ... Connance, a leading provider of healthcare ... predictive analytics drive reimbursement optimization, with a focus on denial management and claims ... “The traditional approach to denied and underpaid claims leaves money on the table ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... has published a new eBook titled “ 5 Questions to Ask Before Entering ... Analyst on the Genetic Test Evaluation (GTE) team, the book explores the various ...
(Date:6/20/2017)... ... , ... HOUSTON – Brazos Towers at Bayou Manor is proud to ... for today’s modern senior. Brazos Towers at Bayou Manor has more than 50 years ... them the services to support that lifestyle both now and in the future. Instead ...
Breaking Medicine News(10 mins):